美国上市的优尼克公司(UniQure)股价上涨61%,因其获得美国食品药品监督管理局(FDA)批准提交亨廷顿舞蹈症基因疗法的申请。
本文源自:金融界AI电报
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.